Search studies using keywords
3,811 Studies in the database containing data with -log p ≥ 0 (showing 161-180)
Pages: 1 2 3 4 5 6 7 8 9 10 >>
No data sets (in No Studies) added to Browser
Identifier Name Phenotype(s) Total p-values Related citationsAdd data sets to Browser Related data
HGVST3666 plus GWAS of Attention deficit hyperactivity disorder 
  • Attention deficit hyperactivity disorder symptom score
1
HGVST3639 plus GWAS of General glucose level in pregnancy 
  • Fasting glucose in pregnancy (gestational week 14-16)
  • Two-hour glucose in pregnancy (gestational week 30-32)
  • General glucose level in pregnancy (gestational week 30-32)
4
HGVST3640 plus GWAS of Response to opioid analgesics in cancer 
  • Response to opioid analgesics in cancer (pain decrease)
2
HGVST3641 plus GWAS of Proliferative diabetic retinopathy 
  • Proliferative diabetic retinopathy (vs NPDR and no DR)
  • Diabetic retinopathy (moderate NPDR and PDR)
  • Proliferative diabetic retinopathy (vs no DR)
  • Diabetic retinopathy (all NPDR and PDR)
77
HGVST3642 plus GWAS of Cardiometabolic traits 
  • Hip circumference
  • Waist-hip ratio
  • Waist circumference
  • Weight
  • Body mass index
  • Lipoprotein (a) levels
11
HGVST3643 plus GWAS of Blood pressure 
  • Pulse pressure
  • Diastolic blood pressure
  • Systolic blood pressure
757
HGVST3644 plus GWAS of Mucinous colorectal cancer 
  • Mucinous adenocarcinoma in colorectal cancer
16
HGVST3645 plus GWAS of Lung cancer 
  • Lung cancer (SNP x SNP interaction)
  • Lung cancer
  • Lung cancer in ever smokers
2
HGVST3646 plus GWAS of Scars after burn injury 
  • Postburn scar pliability
  • Postburn scar height
6
HGVST3647 plus GWAS of Diabetic macular edema and proliferative diabetic retinopathy 
  • Diabetic macular edema in type 2 diabetes
  • Proliferative diabetic retinopathy in type 2 diabetes
4
HGVST3648 plus GWAS of Frontal fibrosing alopecia 
  • Frontal fibrosing alopecia
34
HGVST3649 plus GWAS of Attention deficit hyperactivity disorder and cannabis use 
  • Attention deficit hyperactivity disorder or cannabis use
16
HGVST3650 plus GWAS of Primary central nervous system lymphoma 
  • Primary central nervous system lymphoma
7
HGVST3651 plus GWAS of Medication use 
  • Medication use (antidepressants)
  • Medication use (thyroid preparations)
  • Medication use (antihistamines for systemic use)
  • Medication use (antihypertensives)
  • Medication use (immunosuppressants)
  • Medication use (calcium channel blockers)
  • Medication use (anilides)
  • Medication use (drugs affecting bone structure and mineralization)
  • Medication use (antiglaucoma preparations and miotics)
  • Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease)
  • Medication use (agents acting on the renin-angiotensin system)
  • Medication use (adrenergics, inhalants)
  • Medication use (diuretics)
  • Medication use (drugs used in diabetes)
  • Medication use (glucocorticoids)
  • Medication use (salicylic acid and derivatives)
  • Medication use (beta blocking agents)
  • Medication use (opioids)
  • Medication use (anti-inflammatory and antirheumatic products, non-steroids)
  • Medication use (antimigraine preparations)
  • Medication use (vasodilators used in cardiac diseases)
  • Medication use (antithrombotic agents)
  • Medication use (HMG CoA reductase inhibitors)
910
HGVST3620 plus GWAS of Delayed reward discounting 
  • Delayed reward discounting
5
HGVST3621 plus GWAS of Executive function in ADHD 
  • Executive function in ADHD
1
HGVST3622 plus GWAS of Hodgkin's lymphoma 
  • Hodgkin's lymphoma
6
HGVST3623 plus GWAS of Cannabis use 
  • Cannabis use
8
HGVST3624 plus GWAS of Psychological resilience 
  • Psychological resilience (outcome-based)
  • Psychological resilience (self-assessed)
  • Psychological resilience (outcome-based) in high deployment stress exposure
8
HGVST3625 plus GWAS of Duchenne muscular dystrophy 
  • Age at loss of ambulation in Duchenne muscular dystrophy
36